0001104659-26-026759
SEC filingCentury Therapeutics, Inc. (IPSC) reported significant financial improvement in FY 2025, achieving a net loss of -$9.6M compared to -$126.6M in FY 2024, driven by $109.2M collaboration revenue from the terminated Bristol-Myers Squibb agreement, up from $6.6M. Total operating expenses declined 12% to $126.4M from $144.7M, with R&D at $95.7M (down from $107.2M) and G&A at $24.0M (down from $33.2M), offset by $6.8M long-lived asset impairment and no goodwill impairment (vs. $4.3M prior). Loss from operations narrowed to -$17.3M from -$138.1M. Other income of $7.6M included $7.3M interest income. Balance sheet strengthened with $223.7M total assets, $120.8M current assets (cash $61.9M, short-term investments $55.3M), and $158.9M stockholders' equity. Cash used in operations was -$103.9M, offset by $107.5M investing inflows. Post-period, $126.7M net proceeds from January 2026 private placement extend runway into Q1 2029. Focus on IND-enabling studies for CNTY-813 (T1D) and CNTY-308 (autoimmune), with cash supporting preclinical advancement amid pipeline reprioritization.
Century Therapeutics delivered markedly improved FY 2025 results with net loss of -$9.6M versus -$126.6M in 2024, a 92% reduction. Key driver was $109.2M collaboration revenue (up from $6.6M) from accelerated recognition of remaining Bristol-Myers Squibb transaction price post-termination. Loss from operations narrowed to -$17.3M from -$138.1M. Total operating expenses fell 12% to $126.4M, reflecting pipeline reprioritization, workforce reduction, and lower collaboration costs. R&D expenses declined to $95.7M from $107.2M; G&A to $24.0M from $33.2M. Impairments totaled $6.8M (long-lived assets) versus $4.3M goodwill prior year. Other income $7.6M included $7.3M interest. Balance sheet: total assets $223.7M (down from $353.2M due to revenue recognition), equity $158.9M. Cash burn moderated with operating use -$103.9M versus -$110.1M.
All FY 2025 revenue of $109.2M derived from Bristol-Myers Squibb collaboration, fully recognized upon March 2025 termination (vs. $6.6M in 2024). No product sales; no segment breakdowns disclosed. Post-termination, no future collaboration revenue expected. Management notes potential from future partnerships, but none specified. Geographic mix not detailed; operations primarily U.S.-based.
No gross profit reported (no COGS; collaboration revenue non-product). Operating margin improved implicitly to -16% from -2095% (loss from operations -$17.3M on $109.2M revenue vs. -$138.1M on $6.6M). Cost structure: R&D 76% of op ex (down from 74%), G&A 19% (up from 23%). Efficiencies from reprioritization, lease gains ($1.4M), contingent liability reduction ($4.5M). Stock-based comp fell to $6.8M from $12.7M. Impairments impacted profitability.
Operating cash use -$103.9M (vs. -$110.1M), driven by net loss offset by non-cash items ($20.3M) and deferred revenue drawdown (-$109.2M). Investing provided $107.5M (securities sales $159.5M net purchases -$51.2M). Financing $0.2M (stock exercises). Ending cash/restricted $65.0M; liquidity $117.2M. Total assets $223.7M (current $120.8M); liabilities $64.8M (current $20.2M, deferred revenue $0). Equity $158.9M; accumulated deficit -$791.9M. No debt; post-period $126.7M financing bolsters position.
Cash runway into Q1 2029 supports CNTY-813 (T1D beta islet, IND H2 2026), CNTY-308 (CD19 CAR-iT, IND-enabling), CNTY-101 CARAMEL IST data 2026. Pipeline reprioritization discontinued certain trials, focusing resources on Allo-Evasion™ 5.0 programs. Risks: need additional funding, clinical/regulatory delays, manufacturing scale-up. Strategic partnerships eyed for access expansion.